StockData
BeOne Medicines Ltd. logo

BeOne Medicines Ltd. (ONC) KPIs and segments

ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/302571% above fair value
$403.60−9.66 (-2.34%)

Close on Nov 18, 2026Market cap $45.89BP/E 72.2Yield –

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của BeOne Medicines · năm tài chính kết thúc Calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026)

Nhìn nhanh KPI của BeOne Medicines: 38 chỉ số vận hành, trong đó có Consolidated Total Revenue, BRUKINSA (zanubrutinib, BTKi) và TEVIMBRA (tislelizumab, Anti-PD-1), lấy từ 154 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Product revenue($M)4
1,6801,4871,4761,3951,3021,1091,118993921747631595
United States($M)
899766850743685563616504479351313270
China($M)
500465399435429396358370347316267285
Europe - total revenue($M)
20819117416715211711497.581.466.845.730.7
Rest of world - total revenue($M)
73.165.251.035.631.930.721.913.313.04.349.56
BRUKINSA($M)
1,248950
TEVIMBRA($M)
229194
XGEVA($M)
10481.3
Other($M)
37.821.13.01
BLINCYTO($M)
36.525.6
Other Revenue($M)4
25.326.117.313.28.759.798.158.024.733.88186
United States($M)
15.616.612.29.033.863.191.722.0700128
China($M)
6.316.795.104.123.235.245.704.964.713.272.95
Rest of world - total revenue($M)
3.030000000
Europe - total revenue($M)
0.352.6800.071.661.370.741.000.02354.9
KYPROLIS($M)
15.119.4
POBEVCY($M)
9.6311.2
Kỳ báo cáo trước đây (báo cáo lần cuối 2023)4
United States($M)
914782864755694567619505481351313398
China($M)
506472407440433400363376352320271288
Europe - total revenue($M)
20919417416715211911598.382.466.948.785.6
Rest of world - total revenue($M)
76.165.251.035.631.930.721.913.313.01.969.56
Consolidated Total Revenue ($M)($M)
1,7051,5131,4981,4121,3151,1171,1281,002929752634781
BRUKINSA (zanubrutinib, BTKi) — Global Net Product Revenue ($M)($M)4
1,2481,0951,1461,041950792828690637489413358
BRUKINSA — Global Revenue Growth YoY (%)(%)
31.4%38.3%50.8%49.0%62.1%93.0%106.8%131.1%130.0%
BRUKINSA — United States Net Product Revenue ($M)($M)1
893761845739684563616504479352313270
BRUKINSA — United States Revenue Growth YoY (%)(%)
30.5%35.1%37.0%46.6%42.6%60.2%97.0%86.5%114.4%153.3%149.8%
BRUKINSA — Europe Net Product Revenue ($M)($M)1
19618216716315111611397.381.466.830.7
BRUKINSA — Europe Revenue Growth YoY (%)(%)
30.0%57.4%67.8%84.9%73.4%217.2%209.2%242.8%
BRUKINSA — China Net Product Revenue ($M)($M)1
97.29487.492.483.281.167.863.657.449.847.4
BRUKINSA — China Revenue Growth YoY (%)(%)
16.7%15.9%36.2%30.8%41.3%43.0%31.2%19.4%20.8%
TEVIMBRA (tislelizumab, Anti-PD-1) — Global Net Product Revenue ($M)($M)1
229206182191194171154163158145128144
TEVIMBRA — Global Revenue Growth YoY (%)(%)
18.1%20.5%18.0%16.7%22.2%17.8%20.0%12.8%5.9%26.4%12.6%
Amgen In-Licensed Products — Total Net Product Revenue ($M)($M)4
15714211213312611410290.171.950.4
Amgen In-Licensed Products — Revenue Growth YoY (%)(%)
24.5%25.0%11.0%31.0%40.2%58.7%101.5%81.7%
XGEVA (denosumab, RANKL Inhibitor — Amgen In-Licensed) ($M)($M)
10589.97084.281.370.462.563.55543.424.224.5
BLINCYTO (blinatumomab, CD19×CD3 BiTE — Amgen In-Licensed) ($M)($M)
36.53424.230.525.623.920.620.219.114.413.914.9
KYPROLIS (carfilzomib, Proteasome Inhibitor — Amgen In-Licensed) ($M)($M)
15.21717.518.419.419.718.11815.914.112.711.1
POBEVCY (bevacizumab biosimilar — Bio-Thera In-Licensed) ($M)($M)
9.6012.111.910.511.213.713.112.211.616.614.714.1
Other Marketed & Partnered Products — Net Product Revenue ($M)($M)2
37.833.224.520.121.117.921.82623.624.68413.7
REVLIMID (lenalidomide — BMS/Celgene China Partnered) ($M, FY18–FY24)($M)
3.6011.19.1012.216.115
VIDAZA (azacitidine — BMS/Celgene China Partnered) ($M, FY18–FY23)($M)
2.504.30
Total Research & Development Expense ($M)($M)4
612541615524525482542496455461494453
Internal R&D Expense ($M)($M)
365354361320315291315325296289281296
Total External R&D Expense ($M)($M)3
248188255204210191227171159171213157
External Cost of Development Programs ($M)($M)
194158228174183170143149125123167126
Amgen Co-Development Expense Charged to R&D ($M)($M)
30.329.426.930.126.420.722.21722.513.513.716.3
Upfront License & Development Milestone Fees ($M)($M)3
23.30.5000.2020.5062.5511.53537.624.4
Upfront License Payments Expensed to R&D ($M)($M)
200.5000.200.5006000031.815
Development Milestone Payments Expensed to R&D ($M)($M)
3.30035
Cash Payments for Acquired In-Process R&D ($M)($M)
20.5000.7006000031.8015
Accrued External R&D Activities Liability ($M)($M)
16719915712510691.61541121339916392.7
Prepaid R&D Costs ($M)($M)
48.236.152.67076.244.164.360.268.266.860.573
Amgen Collaboration — Total R&D Financing Commitment Expense ($M)($M)4
59.85853.259.352.240.543.833.644.426.630.432.2
Amgen R&D Financing Liability Amortization (Offset to R&D Expense) ($M)($M)
29.528.626.229.325.819.821.616.621.913.116.715.9
Amgen R&D Cost-Share Liability — Total Carrying Value ($M)($M)1
6.2035.764.390.6120146165187204226239255
Amgen R&D Cost-Share Liability — Current Portion ($M)($M)
6.2035.764.390.610911111110484.6826863.6
Amgen Commercial Inventory Purchases (Related-Party) ($M)($M)
13212443.684.273.362.794.743.147.662.250.718.8
Amgen Remaining Co-Development Funding Commitment ($M)($M)
12.572.3130184243295335379413457484518
Profit-Share & Collaboration Reimbursement Expense — Total Net ($M)($M)3
-15.6-15.417.615-17.1-17-82.811.611.910.3-88.811.1
Reimbursement Expense — Cost of Sales ($M)($M)
12.711.2-9-109.507.50-8.70-10.3-9.60-8.60-4-3.20
Reimbursement Expense — Research & Development ($M)($M)
-1.10-0.200.600.40-1.60-0.5010.300.400.700.10-0.40
Reimbursement Expense — Selling, General & Administrative ($M)($M)
-27.1-26.425.924.6-25-23.922.821.621.118.116.914.7
Gross Product Revenue Before Rebates & Returns ($M)($M)1
2,2061,8941,7711,6581,4001,2461,167945811732
Sales Rebates, Returns & Discounts Deducted from Gross Revenue ($M)($M)
526406376356292252246198180136
Accrued Sales Rebates & Returns Reserve — Ending Balance ($M)($M)2
486440399383297260236214173186140112
Provision for Sales Rebates & Returns Charged to Revenue ($M)($M)
526406426376356292312252246198180136
Payments & Credits Applied Against Sales Rebates & Returns Reserve ($M)($M)
479382382292301283274219245153131110
Accrued Commercial Activities Liability ($M)($M)
13212311912599.876.877.580.870.674.887.660.7
GAAP Gross Margin (% of Global Product Sales)(%)3
90.0%89.0%90.4%85.9%87.4%85.1%85.6%83.0%85.0%83.0%83.2%83.8%
Non-GAAP Adjusted Gross Margin (% of Global Product Sales, FY23–FY25)(%)
90.7%86.3%88.1%85.5%87.4%84.9%85.4%83.7%83.7%
GAAP Cost of Sales — Product ($M)($M)
17516714219716516516117113812510696.3
Non-GAAP Adjusted Cost of Sales — Product ($M)($M)
16716113719115516114115013412110393.0
Non-GAAP Adjusted Operating Expenses ($M)($M)3
1,0359381,016880886817908786746778799705
Non-GAAP Adjusted Research & Development Expense ($M)($M)
534466545446444421475406383405437396
Non-GAAP Adjusted Selling, General & Administrative Expense ($M)($M)
501472471434442396433381364372361308
GAAP SG&A Expense as % of Product Sales (%)(%)
35.0%37.0%38.0%38.0%41.0%41.0%45.0%46.0%48.0%57.0%66.0%61.0%
Non-GAAP Adjusted Operating Income (Loss) ($M)($M)2
50341434434127513978.665.648.5-147-267-16.3
Non-GAAP Adjusted Net Income (Loss) ($M)($M)
44437522530425313616.151.623.3-146
Non-GAAP Free Cash Flow ($M)($M)
435161380354220-12.3-17.354.7-206
GAAP Diluted Earnings (Loss) per ADS ($/ADS, 1 ADS = 13 Ordinary Shares)($)7
2.051.961.090.840.01-1.15-1.15-2.412.01
GAAP Basic Earnings (Loss) per ADS ($/ADS)($)
2.122.051.130.870.01-1.15-1.15-2.412.06
Non-GAAP Adjusted Diluted Earnings (Loss) per ADS ($/ADS)($)
3.843.241.952.652.251.220.150.480.22-1.40
Non-GAAP Adjusted Basic Earnings (Loss) per ADS ($/ADS)($)
3.983.382.032.762.331.270.150.490.22-1.40
Non-GAAP Adjusted Diluted Earnings (Loss) per Ordinary Share ($/sh)($)
0.300.250.150.200.170.090.010.040.02-0.11
Non-GAAP Adjusted Basic Earnings (Loss) per Ordinary Share ($/sh)($)
0.310.260.160.210.180.100.010.040.02-0.11
Weighted-Average Diluted ADSs Outstanding (M ADSs)(M)
116116115113111106105104107
Weighted-Average Basic ADSs Outstanding (M ADSs)(M)
112111110108107106105104105
Total Net Inventories ($M)($M)3
733682608532503495495432443447416317
Raw Materials Inventory ($M)($M)
26727423617918117717114714415814994
Work in Process (WIP) Inventory ($M)($M)
11410912310198.96760.16259.549.439.140
Finished Goods Inventory ($M)($M)
351298249252223250264222240240228183
Property, Plant & Equipment, Net ($M)($M)3
1,6431,6411,6421,6281,6161,5991,5781,5631,5171,4181,3241,178
Property, Plant & Equipment, Gross ($M)($M)6
2,1102,0772,0431,9851,7151,4371,3241,304942900833768
PP&E Gross — Buildings ($M)($M)
1,2051,1971,1881,168933704608608305281232215
PP&E Gross — Manufacturing Equipment ($M)($M)
289283274267259252244249227217187173
PP&E Gross — Laboratory Equipment ($M)($M)
329319310290270250241236217211205187
PP&E Gross — Leasehold Improvements ($M)($M)
79.577.276.673.874.563.164.760.760.459.460.153.1
PP&E Gross — Software & Computer Equipment ($M)($M)
13613012411510710210083.867.766.783.374.8
PP&E Gross — Land & Land Use Rights ($M)($M)
71.471.471.471.471.465.565.565.565.565.565.565.5
Accumulated Depreciation — PP&E ($M)($M)
620574529486453428399366289265249221
Capital Expenditures Incurred but Not Yet Paid ($M)($M)
5.9043.25.20-5.90-2.1060-5-40.215.1101-15.812.2
Finite-Lived Intangible Assets, Net ($M)($M)9
6161.762.763.664.950.151.153.953.755.257.153.7
Finite-Lived Intangible Assets, Gross ($M)($M)2
88.587.486.585.685.372.271.973.872.172.473.366.7
Gross Intangibles — Developed Technology Rights ($M)($M)
79.578.477.576.676.363.262.964.863.163.464.358.4
Gross Intangibles — Licensing Agreements ($M)($M)
999999999990.80
Accumulated Amortization — Finite-Lived Intangible Assets ($M)($M)2
27.525.723.82220.42220.819.918.417.216.113.1
Accumulated Amortization — Developed Technology Rights ($M)($M)
1917.215.313.611.913.612.411.510.18.907.806.60
Accumulated Amortization — Licensing Agreements ($M)($M)
8.508.508.508.508.408.408.408.408.308.308.300.80
Net Intangibles — Developed Technology Rights ($M)($M)
60.561.262.26364.349.650.553.45354.556.551.8
Net Intangibles — Licensing Agreements ($M)($M)
0.500.500.500.500.600.600.600.600.700.700.700
Amortization of Intangible Assets — Total ($M)($M)2
1.601.801.601.605.801.201.201.301.201.2032.30
Amortization of Intangible Assets — Cost of Sales ($M)($M)
1.601.701.501.505.801.201.201.201.201.201.101
Amortization of Intangible Assets — Operating Expenses ($M)($M)
00000000.10001.801.30
Estimated Intangible Amortization — Next 12 Months / Year 1 ($M)($M)
6.508.106.308.306.204.804.804.904.804.8056.20
Estimated Intangible Amortization — Year 2 ($M)($M)
6.508.106.308.306.204.804.804.904.804.8056.20
Estimated Intangible Amortization — Year 3 ($M)($M)
6.508.106.308.306.204.804.804.904.804.8056.20
Estimated Intangible Amortization — Year 4 ($M)($M)
6.508.106.308.306.204.804.804.904.804.804.806.20
Operating Lease Right-of-Use (ROU) Assets ($M)($M)2
14614614814014614613910110487.895.298.7
Operating Lease Liabilities — Current ($M)($M)
21.920.620.715.717.218.317.617.717.719.421.923.2
Operating Lease Liabilities — Noncurrent ($M)($M)
48.249.752.951.453.954.944.332.535.417.722.225.5
Current Portion of Long-Term Debt & Bank Loans ($M)($M)2
19111657.3808764852864852827688329
Noncurrent Long-Term Debt & Bank Loans ($M)($M)
882963962146160167188185199198203
Noncurrent Portion of RMB-Denominated Bank Loans (RMB M)(M)
1,2151,3161,3471,4371,4031,478
Unrecognized Tax Benefits (UTB) — Ending Balance ($M)($M)3
26.128.527.82221.517.617.217.615.814.914.313.9
Deferred Income Tax Liabilities, Net ($M)($M)
57.455.953.247.144.143.14215.915.916.416.516.4
Income Taxes Paid, Net ($M)($M)
70.6-2.7020.72.9067.79.3014.79.1043.12.5013.510
Noncurrent Value-Added Tax (VAT) Receivable ($M)($M)
3.803.603.503.303.103.102.902.802.602.802.502
Total Share-Based Compensation Expense ($M)($M)2
13812312414115195.510811513188.792.896.1
Share-Based Compensation — Research & Development ($M)($M)
58.553.952.458.864.441.84547.755.43839.444.1
Share-Based Compensation — Selling, General & Administrative ($M)($M)
78.969.5718286.253.762.866.975.350.753.352
Global Full-Time Employees (Form 10-K / 10-Q & ESG Report)
12,00012,00012,00012,00011,00011,00011,00010,00010,00010,000
Income Statement — Total revenue ($M)($M)13
1,7051,5131,4981,4121,3151,1171,1281,002929752634781
Cost of sales — product ($M)($M)
17516714219716516516117113812510696.3
Gross profit ($M)($M)
1,5311,3461,3561,2161,151952967831791627529685
Research and development expense ($M)($M)
612541615524525482542496455461494453
Selling, general and administrative expense ($M)($M)
593555555529538459505455444427418366
Total operating expenses ($M)($M)
1,2061,0961,1711,0531,0639411,047951898888912819
Income (loss) from operations ($M)($M)
32525018516387.911.1-79.4-120-107-261-384-134
Income (loss) before income taxes ($M)($M)
31325914914799.520.9-85.4-98.3-106-243-351229
Income tax expense ($M)($M)
75.531.982.722.35.2019.666.52314.57.7016.813.9
Net income (loss) ($M)($M)
23722766.512594.31.30-152-121-120-251-368215
Earnings (loss) per ordinary share — Basic ($/sh)($)
0.160.160.090.070-0.09-0.09-0.190.16
Earnings (loss) per ordinary share — Diluted ($/sh)($)
0.160.150.080.060-0.09-0.09-0.190.15
Weighted-average basic ordinary shares outstanding (M)(M)
1,4511,4431,4331,4081,3901,3771,3611,3561,361
Weighted-average diluted ordinary shares outstanding (M)(M)
1,5051,5051,4891,4631,4451,3771,3611,3561,390
Balance Sheet — Total assets ($M)($M)12
9,1768,5548,1897,6336,2985,8425,9215,8315,7125,6685,8055,525
Cash and cash equivalents ($M)($M)
5,0984,7924,5484,0372,7562,5162,6392,7022,5932,7933,1723,067
Accounts receivable, net ($M)($M)
1,056938865863771717676569529435358309
Inventories, net ($M)($M)
733682608532503495495432443447416317
Total current assets ($M)($M)
7,2166,6016,2345,6654,3103,8973,9923,9123,8393,9084,2034,054
Property, plant and equipment, net ($M)($M)
1,6431,6411,6421,6281,6161,5991,5781,5631,5171,4181,3241,178
Intangible assets, net ($M)($M)
6161.762.763.664.950.151.153.953.755.257.153.7
Accounts payable ($M)($M)
470424479384361365405308333357315342
Total current liabilities ($M)($M)
2,1191,8121,8292,3682,2101,9842,2152,0251,9391,8821,8101,283
Long-term bank loans ($M)($M)
882963962146160167188185199198203
Total liabilities ($M)($M)
4,0023,7933,8273,5032,5282,3422,5892,3952,3462,3072,2681,762
Accumulated deficit ($M)($M)
-7,856-8,093-8,320-8,386-8,511-8,606-8,607-8,455-8,334-8,213-7,962-7,595
Total shareholders' equity ($M)($M)
5,1744,7604,3614,1293,7713,5003,3323,4363,3663,3603,5373,763
Cash Flow Statement — Operating cash flow ($M)($M)4
46320141740326444.175.2188-95.6-309-222-78.1
Capital expenditures ($M)($M)
27.540.837.548.143.856.492.5134110157157158
Share-based compensation expense ($M)($M)
13812312414115195.510811513188.792.996.1
Investing cash flow ($M)($M)
-49.4-45.5-38.3-49.3-66.6-122-93.6-134-111-210-62.6-186
Financing cash flow ($M)($M)
-6.1068.696.996135-33.8-4.5012.723162347-76.8

7 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Fiscal calendar & corporate identity: BeOne Medicines Ltd. (formerly BeiGene, Ltd.; redomiciled to Basel, Switzerland and renamed in May 2025; NASDAQ: ONC, HKEX: 06160, SSE STAR: 688235; 1 ADS = 13 ordinary shares) operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026; latest HKEX monthly return Sep 2026). BeOne operates as a single global oncology operating segment.
  • Core commercial, STAR Market & R&D KPIs (Groups 1–6) cover: (1) Consolidated Revenue ($1,705.1M in Q2 2026 / $5,343.0M in FY25: Net Product Revenue $1,679.8M in Q2 2026 / $5,282.1M in FY25 and Collaboration/Other Revenue $25.3M in Q2 2026 / $61.0M in FY25) disaggregated across United States ($919.6M in Q2 2026 / $2,866.8M in FY25), China ($451.7M in Q2 2026 / $1,572.6M in FY25), Europe ($260.7M in Q2 2026 / $621.8M in FY25), and Rest of World ($73.1M in Q2 2026 / $281.8M in FY25); (2) Commercial Oncology Portfolio by medicine & region: BRUKINSA ($1,247.6M in Q2 2026 / $3,928.5M in FY25, +31.4% YoY in Q2 2026: U.S. $892.5M / +30.5%, Europe $206.4M / +37.3%, China $106.0M / +27.5%, RoW $42.7M / +30.6%), TEVIMBRA ($228.5M in Q2 2026 / $737.3M in FY25, +18.1% YoY in Q2 2026), Amgen in-licensed portfolio ($141.0M in Q2 2026 / $486.2M in FY25: XGEVA $104.5M, BLINCYTO $36.5M, KYPROLIS $17.8M in Q2 2026), POBEVCY ($14.6M in Q2 2026 / $62.0M in FY25), and legacy BMS/Celgene partnered brands; (3) SSE STAR Market (688235.SS) exclusive operational disclosures: physical production/purchase volume (6.27M vials in FY25), physical sales volume (6.00M vials in FY25), ending inventory (2.91M vials in FY25) of key self-developed/in-licensed products, and regional product gross margin split between Ex-China (94.75% in FY25) and Mainland China (70.11% in FY25); (4) R&D Expense ($562.1M in Q2 2026 / $2,145.9M in FY25) split into Internal R&D ($329.8M in Q2 2026 / $1,254.0M in FY25) and External R&D ($232.2M in Q2 2026 / $891.9M in FY25), 9-year molecule-level external R&D allocation from STAR Market reports (BRUKINSA, TEVIMBRA, Sonrotoclax/BEQALZI, BGB-16673/Tacabrutideg, BGB-43395), and Amgen/Novartis collaboration accounting; (5) Gross-to-Net (GTN) sales rebates deducted ($525.8M in Q2 2026) and Accrued Sales Rebates & Returns Reserve rollforward ($485.9M at Q2 2026); and (6) GAAP vs. Non-GAAP Gross Margin (90.0% GAAP in Q2 2026; 87.3% GAAP / 87.8% Adjusted in FY25), SG&A as % of product sales (35% in Q2 2026 vs. 80% in Q1 2023), Adjusted Operating Income ($517.8M in Q2 2026 / $1,100.0M in FY25), Adjusted Net Income ($446.1M in Q2 2026 / $917.6M in FY25), Non-GAAP Free Cash Flow ($429.9M in Q2 2026 / $941.7M in FY25), and GAAP/Adjusted EPS per ADS.
  • Groups 7–11 cover: (7) 74 consecutive months of HKEX Form FF301 Monthly Returns (2020-08..2026-09): HKEX ordinary shares (1,427.23M at Sep 2026), SSE STAR RMB shares (115.06M at Sep 2026), 2016 Plan options outstanding (51.32M at Sep 2026), monthly grants/cancellations/exercises, BG NC 2, Ltd. award pool utilization (74.69M shares issued through Sep 2026), and monthly cash proceeds from option exercises ($7.99M in Sep 2026); (8) Manufacturing inventory by stage ($766.3M net at Q2 2026), PP&E by category ($1,613.5M net at Q2 2026), finite-lived intangibles & 5-year amortization schedule, and operating leases; (9) USD & RMB debt facilities, Unrecognized Tax Benefits rollforward ($65.4M at Q2 2026), Share-Based Compensation ($137.5M in Q2 2026), Issued U.S. (88) & China (77) patents at FY25, and DEF 14A CEO Pay Ratio (171:1 in FY25) & Pay vs. Performance; (10) Global Workforce (12,200 employees at Q2 2026 / 11,760 at FY25 across 5 regions; 2,520 new hires and 10.6% voluntary turnover in FY25), safety (0.14 TRIR / 0.08 LTIR in FY25), and Scope 1/2/3 GHG emissions, energy, water, and waste (FY19–FY25); and (11) FRED pharmaceutical benchmarks and DB financial statements.
  • Swiss Standalone Statutory Financial Statements (prepared in CHF under the Swiss Code of Obligations for parent holding company BeOne Medicines Ltd., 2025) report CHF 490.2M in dividend income from subsidiaries and no external product revenue, and are in a different currency (CHF vs. USD) and accounting basis from U.S. GAAP consolidated statements; therefore no Consolidated − Standalone subtraction is performed. The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.

Dữ liệu cập nhật 2026-10-29.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Consolidated Revenue by Type & Geographic Region ($M)

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của BeOne Medicines

See a number that looks wrong?